The Pamoja Tulinde Maisha (PALM) study logo. “Pamoja Tulinde Maisha” is a Swahili phrase which roughly translates to “Together Save Lives.”
The Pamoja Tulinde Maisha (PALM) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on November 20, 2018 in the Democratic Republic of the Congo (DRC) as part of the emergency response to an ongoing Ebola outbreak in the North Kivu and Ituri Provinces. As of August 9, 2019, the trial had enrolled 681 patients toward an enrollment total of 725.
The study is being run by the World Health Organization (WHO) and The National Institutes of Health (NIH) and is taking place at four Ebola Treatment Centers (ETCs) in Beni, Katwa, Butembo and Mangina. These ETCs have been overseen by staff from the Institut National de Recherche Biomédicale (INRB); the DRC Ministry of Health; and three medical humanitarian organizations: the Alliance for International Medical Action (ALIMA), the International Medical Corps (IMC), and Médecins Sans Frontières (MSF).
As a member of the trial steering committee, Dr. Adam C. Levine, Professor of Emergency Medicine and Director of the Center for Human Rights and Humanitarian Studies at Brown University is supporting the implementation of this study with technical and research expertise.